Neurocrine Biosciences (NBIX) Treasury Shares (2010 - 2025)

Neurocrine Biosciences has reported Treasury Shares for 15 years, with the latest figure at $2.6 million in Q4 2025.

• For the quarter ending Q4 2025, Treasury Shares rose 550.0% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2025 stood at $2.6 million (up 550.0% YoY), and the FY2025 full-year result was $2.6 million, up 550.0% from the prior year.
• Treasury Shares for Q4 2025 stood at $2.6 million, up from $1.5 million in the prior quarter.
• The five-year high for Treasury Shares was $2.6 million in Q4 2025, with the low at $300000.0 in Q4 2023.
• Historically, Treasury Shares has averaged $1.5 million across 5 years, with a median of $1.5 million in 2025.
• Annual changes were most pronounced in 2021 — Treasury Shares surged 900.0% — and 2023, when it slumped 86.96%.
• Neurocrine Biosciences' Treasury Shares stood at $2.0 million in 2021, then grew by 15.0% to $2.3 million in 2022, then tumbled by 86.96% to $300000.0 in 2023, then jumped by 33.33% to $400000.0 in 2024, then surged by 550.0% to $2.6 million in 2025.
• The last three Treasury Shares figures came in at $2.6 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.